Company / Cost of Revenue
Viridian Therapeutics, Inc.\DE Cost of Revenue History
FY2016-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.5M
FY2016
5-year range
-
FY2016-FY2016
Trend
+3.1%
vs FY2015
Sector context
#78 of 85
Health Care
What the data says
Among 85 Health Care companies, Viridian Therapeutics, Inc.\DE is in the top 8% for cost of revenue.
Based on SEC 10-K filings.
$3M in FY2016.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 85This company $2.5M Sector average $2.0B
▼
-99.9% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $2.5M | +3.1% |
As of FY2016 · SEC 10-K · Updated Jun 30, 2026